These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33076397)

  • 1. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance.
    Archer M; Dogra N; Kyprianou N
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33076397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling Prostate Cancer Therapeutic Resistance.
    Wade CA; Kyprianou N
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
    Nepali PR; Kyprianou N
    Front Endocrinol (Lausanne); 2023; 14():1160267. PubMed ID: 37091854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Begemann D; Anastos H; Kyprianou N
    Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
    Livas L; Hasani S; Kyprianou N
    Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
    Hendrix LN; Hamilton DA; Kyprianou N
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation in prostate cancer progression and therapeutic targeting.
    Stark T; Livas L; Kyprianou N
    Transl Androl Urol; 2015 Aug; 4(4):455-63. PubMed ID: 26816843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoskeleton targeting value in prostate cancer treatment.
    Martin SK; Kamelgarn M; Kyprianou N
    Am J Clin Exp Urol; 2014; 2(1):15-26. PubMed ID: 25374905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiota and the landscape of the prostate tumor microenvironment.
    Gupta KR; Kyprianou N
    Am J Clin Exp Urol; 2023; 11(5):352-360. PubMed ID: 37941651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?
    Rennebeck G; Martelli M; Kyprianou N
    Cancer Res; 2005 Dec; 65(24):11230-5. PubMed ID: 16357123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.
    Cao Z; Livas T; Kyprianou N
    Crit Rev Oncog; 2016; 21(3-4):155-168. PubMed ID: 27915969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms navigating the TGF-β pathway in prostate cancer.
    Cao Z; Kyprianou N
    Asian J Urol; 2015 Jan; 2(1):11-18. PubMed ID: 29051866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance.
    Kim YJ; Choi WI; Jeon BN; Choi KC; Kim K; Kim TJ; Ham J; Jang HJ; Kang KS; Ko H
    Toxicology; 2014 Aug; 322():23-33. PubMed ID: 24793912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-mesenchymal transition in prostate cancer: an overview.
    Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
    Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.
    Grant CM; Kyprianou N
    Transl Androl Urol; 2013 Sep; 2(3):202-211. PubMed ID: 25346895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.
    Hao Y; Baker D; Ten Dijke P
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition.
    Song W; Mazzieri R; Yang T; Gobe GC
    Front Immunol; 2017; 8():1106. PubMed ID: 28955335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.
    Cao Z; Koochekpour S; Strup SE; Kyprianou N
    Oncotarget; 2017 Oct; 8(45):78507-78519. PubMed ID: 29108245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.